Most patients with diabetes die from macrovascular complications. Little is known about the pathogenesis of diabetic vascular disease, but recent advances in molecular genetics and oxidation chemistry provide clues to the mystery of diabetes and atherosclerosis. Genetic variants of well-known proteins such as lipoprotein lipase and apolipoprotein E are common. These proteins are suitable candidates for mediating diabetic vascular risk because their variants can produce hypertriglyceridemia, a risk factor for atherosclerosis in diabetes. However, mutations could have different effects on lipoprotein flux across arteries depending on whether expression is dominant in the vascular space or the vascular wall. Lipoproteins retained in the arterial wall are subject to oxidative modification, which could be dependent on glycoxidation, the enzyme myeloperoxidase, or reactive nitrogen species derived from nitric oxide. Accelerated vascular disease in diabetes is likely the result of complex interactions between metabolic derangements such as hyperglycemia, mutations in genes controlling lipid metabolism, and antioxidant defense mechanisms.
Skip Nav Destination
Article navigation
Perspectives in Diabetes|
March 01 1997
The Mystery of Diabetes and Atherosclerosis: Time for a New Plot
Clay F Semenkovich;
Clay F Semenkovich
From the Departments of Medicine, Cell Biology and Physiology, and Molecular Biology and Pharmacology, Washington University School of Medicine
St. Louis, Missouri
Search for other works by this author on:
Jay W Heinecke
Jay W Heinecke
From the Departments of Medicine, Cell Biology and Physiology, and Molecular Biology and Pharmacology, Washington University School of Medicine
St. Louis, Missouri
Search for other works by this author on:
Address correspondence and reprint requests to Dr. Clay F. Semenkovich or Dr. Jay W. Heinecke, Division of Atherosclerosis, Nutrition, and Lipid Research, Washington University School of Medicine, Box 8046, 660 South Euclid Ave., St. Louis, MO 63110. [email protected] or [email protected].
1
AGE, advanced glycation end product; apo, apolipoprotein; CETP, cholesteryl ester transfer protein; CML, Nε-(carboxymethyl)lysine; FAS, fatty acid synthase; IDL, intermediate-density lipoprotein; LPL, lipoprotein lipase.
Diabetes 1997;46(3):327–334
Article history
Received:
June 17 1996
Revision Received:
November 04 1996
Accepted:
November 04 1996
PubMed:
9032085
Citation
Clay F Semenkovich, Jay W Heinecke; The Mystery of Diabetes and Atherosclerosis: Time for a New Plot. Diabetes 1 March 1997; 46 (3): 327–334. https://doi.org/10.2337/diab.46.3.327
Download citation file:
142
Views